Form 4: Clene Inc. Executive Mark Mortenson Reports Stock Option Grant

Mark Mortenson, Chief Science Officer of Clene Inc., reports the grant of stock options for 40,000 shares of common stock.

Summary

• On February 24, 2025, Mark Mortenson, the Chief Science Officer of Clene Inc., was granted stock options to purchase 40,000 shares of Clene Inc. common stock.
• The exercise price for these options is $4.23 per share.
• The options were granted under the Clene Inc. Amended 2020 Stock Plan.
• 25% of the options vest on February 24, 2026, with the remaining options vesting in 36 equal monthly installments starting March 24, 2026.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral-to-positive event.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule incentivizes long-term commitment from the Chief Science Officer.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with company performance.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• The vesting schedule, with an initial cliff followed by monthly installments, is also a common practice.
• Comparable companies often use similar equity-based compensation to incentivize key personnel.

Stakeholder Impact

• Shareholders may view the option grant as a positive incentive for the Chief Science Officer to drive company success.
• Employees may see this as a sign of the company's commitment to its leadership.

Key Dates